Asset Details
Do you wish to reserve the book?
Systemic medications and dementia risk: an umbrella review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Systemic medications and dementia risk: an umbrella review
Do you wish to request the book?
Systemic medications and dementia risk: an umbrella review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Systemic medications and dementia risk: an umbrella review
2024
Overview
Background Dementia is a growing global public health challenge. Previous meta‐analyses have found that systemic medications may modulate dementia risk. We aimed to provide an overview of this evidence. Method We conducted an umbrella review of meta‐analyses (PROSPERO CRD42021226307). MEDLINE, AMED, PsycINFO, and Embase were searched from inception to 25th January 2023. Only peer‐reviewed meta‐analyses examining dementia risk and systemic medications in humans were included, with no restrictions on language. Studies examining cognitive decline were excluded. Participant details, study types, diagnostic criteria, publication bias, heterogeneity, and summary effect estimates were extracted from publications. Study quality was assessed using the AMSTAR‐2. Data extraction and quality ratings were carried out independently by two authors. Result 60 studies were included in the final review. Included meta‐analyses examined anti‐hypertensives (n = 17), statins (n = 7), antacids (n = 7), non‐steroidal anti‐inflammatory drugs (NSAIDs) (n = 6), diabetes medications (n = 4), hormone replacement therapy (n = 4), androgen deprivation therapy (ADT) (n = 4), psychotropic medications (n = 4), anticholinergics (n = 3), anticoagulants (n = 2), and vitamin E (n = 2). Number of participants in each review ranged from 842 to 9,162,509. Mean age ranged from 59 to 78 years, and between 0 and 100% of participants were female. There was a trend towards decreased risk of dementia with antihypertensives, statins, NSAIDs, anticoagulants, and vitamin E, and towards increased risk with ADT, benzodiazepines, and anticholinergic medications. Conclusion Available data were primarily observational, leading to biases such as confounding by indication, and few studies met a high number of critical quality criteria. Randomised‐controlled data were rare but supported an association between treatment of hypertension and reduced dementia incidence and a possible association between hormone replacement therapy and increased risk of dementia. Our review provides an overview of what kinds of medication are associated with dementia risk, to guide clinical practice and future research. Currently there are no systemic medications that should be prescribed with the primary aim of reducing dementia risk.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.